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Human melioidosis is associated with a high rate of recurrent disease, despite adequate antimicrobial
treatment. Here, we define the rate of relapse versus the rate of reinfection in 116 patients with 123 episodes
of recurrent melioidosis who were treated at Sappasithiprasong Hospital in Northeast Thailand between 1986
and 2005. Pulsed-field gel electrophoresis was performed on all isolates; isolates from primary and recurrent
disease for a given patient different by one or more bands were examined by a sequence-based approach based
on multilocus sequence typing. Overall, 92 episodes (75%) of recurrent disease were caused by the same strain
(relapse) and 31 episodes (25%) were due to infection with a new strain (reinfection). The interval to recurrence
differed between patients with relapse and reinfection; those with relapses had a median time to relapse of 228
days (range, 15 to 3,757 days; interquartile range [IQR], 99.5 to 608 days), while those with reinfection had a
median time to reinfection of 823 days (range, 17 to 2,931 days; IQR, 453 to 1,211 days) (P  0.0001). A total
of 64 episodes (52%) occurred within 12 months of the primary infection. Relapse was responsible for 57 of 64
(89%) episodes of recurrent infection within the first year after primary disease, whereas relapse was respon-
sible for 35 of 59 (59%) episodes after 1 year (P < 0.0001). Our data indicate that in this setting of endemicity,
reinfection is responsible for one-quarter of recurrent cases. This finding has important implications for the
clinical management of melioidosis patients and for antibiotic treatment studies that use recurrent disease as
a marker for treatment failure.
Melioidosis is a severe infection caused by the gram-negative
bacillus Burkholderia pseudomallei, an environmental sapro-
phyte present in Southeast Asia and northern Australia (17). A
major feature of human disease is that bacterial eradication is
difficult to achieve. The clinical response to intravenous anti-
biotics is slow, with a median fever clearance time in our
patient population of 8.5 days. Although prolonged courses of
antibiotic treatment (at least 10 days of intravenous antibiotics,
followed by 12 to 20 weeks of oral antibiotics) are recom-
mended, recurrent disease is common (at a rate of 6% in the
first year) (2, 5). A prolonged period of dormancy of up to 62
years may also occur between a presumed exposure to B.
pseudomallei and clinical manifestations of infection (9).
Bacterial mechanisms and host susceptibility for recurrent
melioidosis are poorly understood. However, the ability of B.
pseudomallei to survive in the human host supports the idea
that recurrence is more likely to be associated with a relapse
caused by bacteria persisting within a sequestered focus than to
reinfection with a different strain. This is consistent with pre-
vious small studies in which isolates from the first and second
episodes of infection in a given patient usually had the same
genotype (5, 6, 14). Here, we report the results of a large
genotyping study of isolates from 116 patients in Northeast
Thailand with 123 episodes of recurrent melioidosis.
MATERIALS AND METHODS
Patients and bacterial isolates. Patients were prospectively recruited by a
study team based at Sappasithiprasong Hospital, Ubon Ratchathani, northeast
Thailand, between September 1986 and January 2005. Patients with suspected
melioidosis were actively sought during twice-daily rounds of the medical and
intensive care wards, together with passive surveillance of surgical and pediatric
wards. Detailed clinical information was recorded, including a documented his-
tory of culture-proven melioidosis. Blood and throat swab samples were collected
from all patients for culture; other specimens (urine, pus, and surface swabs of
skin lesions) were collected where available and were processed by standard meth-
ods (16). Isolates were stored in Trypticase soy broth with 15% glycerol at 80°C.
PFGE. For all patients with more than one episode of disease, the first B.
pseudomallei isolates cultured on the first and subsequent episodes of melioidosis
were examined by pulsed-field gel electrophoresis (PFGE). A single bacterial
colony was streaked onto Columbia agar and incubated for 48 h at 37°C in air.
The colonies were harvested and suspended to an optical density at 540 nm of 0.7
in suspension buffer (75 mM sodium chloride, 25 mM EDTA, pH 7.5). This was
mixed (1:1) with molten 2% low-melting-point agarose (Ultrapure; Gibco) and
pipetted into PFGE plug molds (Bio-Rad Laboratories, Hercules, CA). The
plugs were lysed overnight at 56°C in lysis buffer (0.1% sodium dodecyl sulfate,
25 mM EDTA, pH 8.0) containing 500 g/ml proteinase K (Invitrogen) and then
rinsed three times with TE buffer (10 mM Tris, 10 mM EDTA). Prior to PFGE,
the plugs were digested overnight with 10 U SpeI (New England Biolabs) at 37°C
before being loaded into a 1% agarose gel (Gibco) in 0.5 TBE buffer (Tris-
borate-EDTA). Each well was overlaid with 0.8% low-melting-point agarose.
PFGE was performed on a CHEF-DRIII system (Bio-Rad Laboratories, Rich-
mond, CA) for 44 h at a temperature of 14°C and at 6 V/cm using the following
parameters: initial switch time, final switch time, and run time for block I, 10 to
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60 V for 18 h; those for block II, 30 to 40 V for 18 h; and those for block III, 50
to 90 V for 8 h. Bacteriophage lambda concatemers were run as the standard
(Promega). Gels were stained with ethidium bromide, washed in water, and
photographed under UV light by using the Gel Doc 1000 system (Bio-Rad).
Analysis of the PFGE banding patterns was performed with BioNumerics (ver-
sion 2.5) software (Applied Maths, Belgium).
MLST. Multilocus sequence typing (MLST) was performed as described pre-
viously (7), with the exception that gmhD was amplified by using a nested
approach with the following primers: outer primer pair, gmhD-up (5-TCGCG
CAGGGCACGCAGTT) and gmhD-dn (GGCTGCCGACCGTGAGACC); in-
ner primer pair, gmhD-up (5-TCGCGCAGGGCACGCAGTT) and gmhD-dn
(GTCAGGAACGGCGCGTCGTAGC). Alleles at each of the seven loci were
assigned, and the allelic profile (presented as a string of seven integers) was used
to define the sequence type (ST) using the B. pseudomallei MLST website
(http://bpseudomallei.mlst.net/).
Colony morphology. The appearance of the colony morphology was examined
for use as a guide to the likelihood of reinfection. Isolates were spread plated to
achieve single colonies on Ashdown’s agar and incubated for 4 days at 37°C in
air. The colony morphologies were compared between the first and subsequent
cultures for each patient.
Definitions and analysis. Recurrent disease was defined as clinical features of
melioidosis in association with one or more cultures positive for B. pseudomallei
in a patient with a history of one or more previous episodes. This included
patients who had completed treatment for the previous episode, together with
patients who had recurrent symptoms while receiving oral antibiotics for melioidosis
following clear initial clinical and microbiological responses to antibiotic therapy.
Disease relapse and reinfection were defined on the basis of the typing of the
isolates from the first episode and the subsequent episode(s). Isolates from the
same patient with identical banding patterns on PFGE were considered to
represent a single isolate, and these patients were classified as having relapse.
Isolates from the same patient that differed by one or more bands were examined
using a screening approach based on MLST. This used the assumption that a
difference in just one of seven MLST loci is sufficient to assign different sequence
types. Two of the seven MLST loci, narK and gmdD, are variable within the
bacterial population. The sequence of narK was first determined, followed by se-
quencing of gmhD for isolate pairs with the same allele narK. Isolates from the same
patient that differed at one or both of these loci were considered to represent
reinfection. Those with sequence identity at both narK and gmhD were further
characterized using the remaining five MLST loci to define the full sequence type.
Statistical tests were performed using Intercooled Stata 8.0 software (Stata
Corporation, College Station, TX). Proportions were compared by Fisher’s exact
test, and continuous variables were compared by the Wilcoxon rank-sum test.
Ethical approval for clinical studies at Ubon Ratchathani has been obtained from
the Ministry of Public Health, Royal Government of Thailand.
RESULTS
A total of 130 patients presented with 145 episodes of a
culture-proven recurrence of melioidosis between September
1986 and January 2005. Of these, four patients had three ep-
isodes of recurrence, seven patients had two episodes of recur-
rence, and the remainder had a single recurrence. Paired iso-
lates were not available for 14 patients, and a further eight
isolates were missing from patients with more than one epi-
sode of recurrent disease. After these isolates were excluded,
isolates from 116 patients with a total of 123 episodes of re-
current disease were available for typing. The time to recur-
rence for 123 episodes ranged from 15 to 3,757 days (10.3
years). The median time to recurrence was 317 days, with an
interquartile range (IQR) of 129 to 930 days.
The PFGE banding patterns were identical for 90 of 123
episodes, including those episodes for five of the six patients
with more than one recurrence. The PFGE banding patterns
differed between isolate pairs in 33 episodes. This included an
episode in one patient with two recurrent infections; the strain
from the first recurrence had the same pattern as that of the
strain from the primary infection, but the second recurrence
was caused by an isolate with a different banding pattern. The
number of bands different between pairs ranged from 1 to 15
(median, 6 bands; IQR, 4 to 7 bands). Sequence analysis of one
or both of narK and gmhD indicated that the isolates were
different for 31 of the 33 episodes. Two isolate pairs that were
one and four bands different, respectively, on PFGE were
identical by full sequence typing of all seven loci. Thus, on the
basis of combined typing, 92 episodes (75%) of recurrence
represented relapsing disease and 31 episodes (25%) were due
to reinfection with a new strain.
Of the six pairs classified as closely related by PFGE (up to
three band differences) by the criteria of Tenover et al. (13), 5
(83%) were found to be different by sequenced-based typing.
Of the 14 pairs classified as possibly related (four to six band
differences), 13 (93%) were found to be different by sequence-
based typing. All 13 pairs with greater than six band differences
were different based on sequence-based typing.
The interval to recurrence differed for episodes due to re-
lapse and reinfection; those caused by relapse had a median
time of 228 days (range, 15 to 3,757 days; IQR, 99.5 to 608
days), while those due to reinfection had a median time of 823
days (range, 17 to 2,931 days; IQR 453 to 1,211 days) (P 
0.0001). The times to recurrence and the proportions due to
reinfection are illustrated in Fig. 1. A total of 64 episodes
(52%) occurred within 12 months of the primary infection.
Recurrent disease was due to relapse in 57 of 64 episodes
(89%) within the first year of the primary episode, in 15 of the
21 episodes (71%) in the second year after the primary epi-
sode, and in 20 of 38 episodes (53%) more than 2 years after
the primary episode.
There were only 12 instances where the colony morphology
was completely different between the isolate pairs associated
with the primary and the recurrent infection. Of these, only five
(42%) represented relapses.
DISCUSSION
Previous studies of recurrent melioidosis have defined sev-
eral clinical risk factors, including adherence to therapy, initial
intravenous therapy, the severity of disease, and the duration
of oral antibiotic therapy (2). Clinical trials have demonstrated
higher recurrence rates in association with the use of doxycy-
cline monotherapy (1), quinolone monotherapy (3), amoxicil-
lin-clavulanate (11), and ciprofloxacin-azithromycin (4) in
eradication therapy. Most of these studies have assumed that
FIG. 1. Time to recurrent disease and proportion of cases due to
reinfection. ■, reinfection; , relapse; Œ, percent reinfection.
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recurrent melioidosis represents a relapse due to recrudes-
cence of the original infecting isolate.
Previous studies appear to support this assumption. In an
earlier study with our population, isolates from 23 of 25 pa-
tients with recurrent disease had identical or highly similar
ribotype patterns, while those for two patients were different
(6). A further study in Thailand reported different PFGE
banding patterns for isolates from 4 of 35 patients with recur-
rent disease (8). In Australia, where recurrent disease was
observed in 27 (13%) of patients over a follow-up period of 10
years, the majority of the cases (25 of 27) were due to relapse
of the original infecting strain based on randomly amplified
polymorphic DNA analysis or PFGE. In these patients, re-
lapsed infection occurred between 1 and 27 months (mean, 8
months) after the primary presentation, whereas the two rein-
fections occurred after 14 months and 4.8 years (5). In a Ma-
laysian study, four of five recurrences were due to relapse of
the original infecting strain, based on ribotyping (14). Our
contrasting findings are likely to reflect the long patient follow-
up, with the longest recurrence occurring more than 10 years
after the initial episode. The previous study with our Thai
patient population had a shorter duration of follow-up, with
only 6 of 25 episodes studied occurring after an interval of
more than 12 months, of which 1 was defined as reinfection.
Use of different typing methods may also be important, since
ribotyping may be less discriminatory than PFGE (10, 15). The
criteria of Tenover et al. (13) have been widely adopted as the
standard for the interpretation of DNA macrorestiction band-
ing patterns in microepidemiological investigations; DNA
macrorestriction patterns that differ by two to three bands are
interpreted as being closely related, and differences of four to
six bands are interpreted as possibly related (13). We used an
unambiguous sequence-based typing system, MLST, to resolve
the uncertainty for the DNA macrorestriction patterns that
suggested that the strains were closely related. Use of these
criteria at the level of “closely related” on PFGE alone would
have led to the misclassification of five patients into the relapse
group and one patient into the reinfection group. The predictive
power of using colony morphology as a surrogate for strain typing
was examined, but it was not found to be useful for this purpose.
In this study, we found that recurrent disease within 12
months was mostly due to relapse of the original infecting
strain, consistent with previous results. However, the propor-
tion of recurrent disease due to reinfection increased after this
time; after 2 years, recurrence was equally due to reinfection as
to relapse. The number of reinfections each year remained
similar. We were unable to calculate a rate of reinfection, due
to uncertainty in the number of patients being followed up at
each point in time, but it is evident that this rate (5 to 8 per
1,000 patients per year) is far greater than the annual incidence in
the community (4.4 per 100,000 population) (12), illustrating the
susceptibility of this group to infection with B. pseudomallei.
This study has important implications for future studies.
After intervals exceeding 12 months, recurrent disease often
represents reinfection rather than recrudescence of the origi-
nal infecting isolate in our population. Studies of oral antibi-
otic eradication therapy for melioidosis that use recurrent dis-
ease as a marker of drug efficacy need to undertake bacterial
typing to accurately distinguish relapse from reinfection, anal-
ogous to studies of antimalarials in areas where melioidosis is
highly endemic. Future typing studies should consider the use
of sequence-based verification of the results for isolates that
are different on PFGE. Patients with previous melioidosis form
a group of individuals who are susceptible to subsequent in-
fection; despite adequate oral eradication therapy, in areas of
endemicity, reinfection following reexposure to environmental
B. pseudomallei is more common than had previously been
appreciated.
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